Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dopa-responsive Dystonia in Children.

Jonathan W. Mink1

  • 1Department of Neurology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 631, Rochester, NY 14642, USA. Jonathan_Mink@urmc.rocheste r.edu

Current Treatment Options in Neurology
|June 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Dopa-responsive dystonia treatment with carbidopa/levodopa offers dramatic symptom relief. This effective therapy is recommended for children presenting with dystonia, regardless of initial symptoms.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • Dopa-responsive dystonia (DRD) is a neurological disorder characterized by involuntary muscle contractions.
  • The condition often presents in childhood, typically with lower extremity dystonia.
  • Genetic defects, such as guanosine triphosphate cyclohydrolase I deficiency, can cause DRD.

Purpose of the Study:

  • To highlight the efficacy and safety of levodopa-based treatments for DRD.
  • To emphasize the importance of considering carbidopa/levodopa for all pediatric dystonia cases.
  • To differentiate levodopa treatment from anticholinergic agents.

Main Methods:

  • Clinical observation of treatment responses in patients with DRD.
  • Review of existing literature on DRD management.

Related Experiment Videos

  • Case studies illustrating the benefits of carbidopa/levodopa.

    • Main Results:

    • Carbidopa/levodopa provides dramatic and complete symptom resolution in DRD.
    • Anticholinergic agents are less effective and carry a higher risk of side effects.
    • Early diagnosis and treatment with carbidopa/levodopa prevent long-term complications.

    Conclusions:

    • Carbidopa/levodopa is the primary and most effective treatment for DRD.
    • A trial of carbidopa/levodopa is recommended for any child diagnosed with dystonia.
    • Prompt treatment ensures excellent outcomes and avoids disease progression.